Patient Organizations Push for Transparency in Pharmaceutical Funding

Patient organizations are increasingly funded by pharmaceutical companies, a practice that has drawn criticism regarding potential conflicts of interest. Dr. Martin Danner, CEO of the German umbrella organization for self-help groups of people with disabilities and chronic illnesses (BAG-Selbsthilfe), stresses the importance of transparency and oversight in managing these relationships.

Danner acknowledges the importance of collaboration between patient groups and the pharmaceutical industry for patient-centered research, given that much of this research is privately funded. However, he cautions that organizations must be vigilant to avoid undue influence when accepting financial support. BAG-Selbsthilfe participates in regulatory processes, such as those of IQWiG and G-BA, where demonstrating independence is critical.

To address concerns, BAG-Selbsthilfe has established clear guidelines on corporate funding. They consider it problematic if more than 15 percent of an organization's budget comes from a single pharmaceutical company, and unacceptable if it exceeds 40 percent. Pharmaceutical industry associations, like vfa and BPI, publish details of their payments to patient groups, complementing industry-specific transparency guidelines.

Danner also points out that funding from statutory health insurance providers often exceeds that from pharmaceutical companies, yet receives less attention. He specifically criticizes project-based funding from insurers, as it can allow for direct influence over an organization's activities. While formal sanctions for non-compliance are rare, the mere publication of a violation can significantly damage an organization's reputation and its ability to secure future funding.